Your browser doesn't support javascript.
loading
Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine
Shohei Yamamoto; Ami Fukunaga; Akihito Tanaka; Junko S Takeuchi; Yosuke Inoue; Moto Kimura; Gohzoh Ueda; kenji Maeda; Tetsuya Mizoue; Mugen Ujiie; Wataru Sugiura; Norio Ohmagari.
Afiliação
  • Shohei Yamamoto; National Center for Global Health and Medicine
  • Ami Fukunaga; National Center for Global Medicine
  • Akihito Tanaka; Center Hospital of the National Center for the Global Health and Medicine
  • Junko S Takeuchi; National Center for Global Medicine
  • Yosuke Inoue; National Center for Global Medicine
  • Moto Kimura; National Center for Global Medicine
  • Gohzoh Ueda; National Center for Global Medicine
  • kenji Maeda; National Center for Global Medicine
  • Tetsuya Mizoue; National Center for Global Medicine
  • Mugen Ujiie; National Center for Global Medicine
  • Wataru Sugiura; National Center for Global Medicine
  • Norio Ohmagari; National Center for Global Medicine
Preprint em Inglês | medRxiv | ID: ppmedrxiv-21260744
ABSTRACT
High vaccine reactogenicities may reflect stronger immune responses, but the epidemiological evidence for coronavirus disease 2019 (COVID-19) vaccines is sparse and inconsistent. We observed that a fever of [≥]38{square} after two doses of the BNT162b2 vaccine was associated with higher severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike IgG titers.
Licença
cc_by_nc_nd
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Idioma: Inglês Ano de publicação: 2021 Tipo de documento: Preprint
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Idioma: Inglês Ano de publicação: 2021 Tipo de documento: Preprint
...